))
Advancements in Heart Failure Clinical Research
Manage episode 425413603 series 2849626
BEaTS Research Radio द्वारा प्रदान की गई सामग्री. एपिसोड, ग्राफिक्स और पॉडकास्ट विवरण सहित सभी पॉडकास्ट सामग्री BEaTS Research Radio या उनके पॉडकास्ट प्लेटफ़ॉर्म पार्टनर द्वारा सीधे अपलोड और प्रदान की जाती है। यदि आपको लगता है कि कोई आपकी अनुमति के बिना आपके कॉपीराइट किए गए कार्य का उपयोग कर रहा है, तो आप यहां बताई गई प्रक्रिया का पालन कर सकते हैं https://hi.player.fm/legal।
Nicole Chu from the University of Ottawa speaks with Dr. Javed Butler. Dr. Javed Butler, MD, MPH, MBA, is the President of the Baylor Scott and White Research Institute, and Senior Vice President and Maxwell A. and Gayle H. Clampitt Endowed Chair at the Baylor Scott and White Health in Dallas, Texas. He is also the Distinguished Professor of Medicine at the University of Mississippi in Jackson, Mississippi. In this episode, Dr. Butler shares with us the major findings from the recent EMPACT-MI clinical trial and his perspective on the future of heart failure therapies. The EMPACT-MI trial investigated whether a medicine called empagliflozin, a SGLT2 inhibitor, helps to lower the risk of heart failure and death in people had experienced a heart attack (myocardial infarction).
Learn more about the EMPACT-MI clinical trial https://www.nejm.org/doi/full/10.1056/NEJMoa2206286
31 एपिसोडस
साझा करें
